SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-002869 to BGM Group Ltd. (BGM)

BGM Group Ltd.
Date: March 17, 2025 · CIK: 0001779578 · Accession: 0000000000-25-002869

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-285635

Date
March 17, 2025
Author
Division of
Form
UPLOAD
Company
BGM Group Ltd.

Letter

Re: BGM Group Ltd. Registration Statement on Form F-3 Filed March 7, 2025 File No. 333-285635 Dear Chen Xin:

March 17, 2025

Chen Xin Chief Executive Officer BGM Group Ltd. No. 152 Hongliang East 1st Street, No. 1703, Tianfu New District, Chengdu, 610200 People s Republic of China

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Joshua Gorsky at 202-551-7836 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Yu Wang, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 17, 2025

Chen Xin
Chief Executive Officer
BGM Group Ltd.
No. 152 Hongliang East 1st Street, No. 1703,
Tianfu New District, Chengdu, 610200
People s Republic of China

 Re: BGM Group Ltd.
 Registration Statement on Form F-3
 Filed March 7, 2025
 File No. 333-285635
Dear Chen Xin:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Joshua Gorsky at 202-551-7836 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Yu Wang, Esq.
</TEXT>
</DOCUMENT>